Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review

References

• Abbott NJ, Romero IA. Transporting therapeutics across the blood–brain barrier. Mol Med Today 1996;2:106–13
   PubMedGoogle Scholar
• Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010;40:385–403
   PubMed Web of Science ®Google Scholar
• Davis SS. Biomedical applications of nanotechnology – implications for drug targeting and gene therapy. Trends Biotechnol 1997;15:217–24
   PubMed Web of Science ®Google Scholar
• Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease. J Control Release 2005;108:193–214
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, et al. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencapsul 2011;29:103–14
   PubMed Web of Science ®Google Scholar
• Chen J, Wang X, Wang J, et al. Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. Eur J Pharm Biopharm 2008;68:694–700
   PubMed Web of Science ®Google Scholar
• Colombo G, Lorenzini L, Zironi E, et al. Brain distribution of ribavirin after intranasal administration. Antiviral Res 2011;92:408–14
   PubMed Web of Science ®Google Scholar
• Ali J, Ali M, Baboota S. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 2010;10:1644–53
   Google Scholar
• Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv 2014;5:709–33
   PubMedGoogle Scholar
• Flachenecker P. Epidemiology of neuro-immunological diseases. J Neurol 2006;253:2–8
   Web of Science ®Google Scholar
• Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007;32:1054–82
   PubMed Web of Science ®Google Scholar
• Cole NB, Murphy DD. The cell biology of alpha-synuclein: a sticky problem? Neuromol Med 2002;1:95–109
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS, Tekade AR, et al. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med 2013;24:2101–15
   PubMed Web of Science ®Google Scholar
• Modi G, Pillay V, Choonara YE, et al. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009;88:272–85
   PubMed Web of Science ®Google Scholar
• Biddlestone-Thorpe L, Marchi N, Guo K, et al. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv Drug Deliv Rev 2012;64:605–13
   PubMed Web of Science ®Google Scholar
• Gomes MJ, Neves J, Sarmento B. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed 2014;9:1757–69
   PubMed Web of Science ®Google Scholar
• Brambilla D, Droumaguet BL, Nicolas J, et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 2011;7:521–40
   PubMed Web of Science ®Google Scholar
• Kanwar RJ, Sun X, Punj V, et al. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine 2012;8:399–414
   PubMed Web of Science ®Google Scholar
• Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas 2012;73:45–51
   PubMed Web of Science ®Google Scholar
• Braak H, Bohl JR, Muller CM, et al. Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006;21:2042–51
   PubMed Web of Science ®Google Scholar
• Linazasoro G. Potential applications of nanotechnologies to Parkinson's disease therapy. Parkinsonism Relat Disord 2008;14:383–92
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:104–53
   Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492–6
   PubMed Web of Science ®Google Scholar
• Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;40:1513–17
   PubMed Web of Science ®Google Scholar
• Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988;45:260–2
   PubMed Web of Science ®Google Scholar
• Mayeux R, Stern Y, Rosen J, et al. Depression, intellectual impairment and Parkinson disease. Neurology 1981;31:645–50
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996;53:175–9
   PubMed Web of Science ®Google Scholar
• Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986;9:357–81
   PubMed Web of Science ®Google Scholar
• Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Rev 2000;31:236–50
   PubMed Web of Science ®Google Scholar
• Lapper SR, Bolam JP. Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 1992;51:533–45
   PubMed Web of Science ®Google Scholar
• Abercrombie ED, Zigmond MJ. Modification of central catecholaminergic systems by stress and injury: functional significance and clinical implications. In: Bloom EJ, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995
   Google Scholar
• Ingham CA, Hood SH, Arbuthnott GW. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res 1989;503:334–8
   PubMed Web of Science ®Google Scholar
• Zaja-Milatovic S, Milatovic D, Schantz AM, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005;64:545–7
   PubMed Web of Science ®Google Scholar
• Villalba RM, Verreault M, Smith Y. Spine loss in the striatum of MPTP treated monkeys. A correlation with the degree of striatal dopaminergic denervation. Exp Neurol 2009;215:220–7
   PubMed Web of Science ®Google Scholar
• Gibb WR, Scott T, Lees AJ. Neuronal inclusions of Parkinson's disease. Mov Disord 1991;6:2–11
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Mori H, Izumiyama N, et al. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 1998;75:345–53
   Google Scholar
• Fergusson J, Landon M, Lowe J, et al. Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci Lett 1996;219:167–70
   PubMed Web of Science ®Google Scholar
• Ii K, Ito H, Tanaka K, et al. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 1997;56:125–31
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000;47:521–3
   PubMed Web of Science ®Google Scholar
• New Insight into Parkinson's Disease_NIH Director's Blog. Available at: www.directorsblog.nih.gov [last accessed 19 Aug 2014]
   Google Scholar
• Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 1992;49:492–7
   PubMed Web of Science ®Google Scholar
• Carlsson A, Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 1976;38:271–6
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33–5
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 1997;276:2045–7
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605–8
   PubMed Web of Science ®Google Scholar
• Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science 2002;299:256–9
   PubMed Web of Science ®Google Scholar
• Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1158–60
   PubMed Web of Science ®Google Scholar
• Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601–7
   PubMed Web of Science ®Google Scholar
• Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595–600
   PubMed Web of Science ®Google Scholar
• Lim KL, Ng CH. Genetic models of Parkinson disease. Biochim Biophys Acta 2009;1792:604–15
   PubMed Web of Science ®Google Scholar
• Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008;116:1–16
   PubMed Web of Science ®Google Scholar
• Arai K, Kato N, Kashiwado K, et al. Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett 2000;296:171–3
   PubMed Web of Science ®Google Scholar
• Choi P, Snyder H, Petrucelli L, et al. SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res 2003;117:179–89
   PubMedGoogle Scholar
• Staropoli JF, McDermott C, Martinat C, et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003;37:735–49
   PubMed Web of Science ®Google Scholar
• Imai Y, Soda M, Inoue H, et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001;105:891–902
   PubMed Web of Science ®Google Scholar
• Corti O, Hampe C, Koutnikova H, et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 2003;12:1427–37
   PubMed Web of Science ®Google Scholar
• Ko HS, von Coelln R, Sriram R, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 2005;25:7968–78
   PubMed Web of Science ®Google Scholar
• Ko HS, Kim SW, Sriram SR, et al. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 2006;281:16193–6
   PubMed Web of Science ®Google Scholar
• An Y, Tang L, Jiang X, et al. A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of α-synuclein. Chemistry 2010;16:14439–46
   PubMed Web of Science ®Google Scholar
• Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007;64:1083–8
   PubMed Web of Science ®Google Scholar
• Bjorklund T, Kirik D. Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochim Biophys Acta 2009;1792:703–13
   PubMed Web of Science ®Google Scholar
• Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 2009;1792:688–702
   PubMed Web of Science ®Google Scholar
• Sahni JK, Doggui S, Ali J. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release 2011;152:208–31
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 2009;6:144–52
   PubMed Web of Science ®Google Scholar
• Banerjee T, Mitra S, Kumar Singh A, et al. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 2002;243:93–105
   PubMed Web of Science ®Google Scholar
• Vyas SP, Khar RK. Targeted and controlled drug delivery: a novel carrier system. New Delhi: CBS Publishers; 2002
   Google Scholar
• Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002;6:319–27
   Web of Science ®Google Scholar
• Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3–19
   PubMed Web of Science ®Google Scholar
• Tan SW, Billa N, Roberts CR. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids Surf A 2010;372:73–9
   Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, et al. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008;1200:159–68
   PubMed Web of Science ®Google Scholar
• Olivier JC. Drug targeting to brain with targeted nanoparticles. NeuroRx 2005;2:108–19
   PubMedGoogle Scholar
• Pathan SA, Iqbal Z, Zaidi SMA, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009;3:71–89
   PubMedGoogle Scholar
• Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 2013;10:957–72
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146–57
   PubMed Web of Science ®Google Scholar
• Dagenais C, Rousselle C, Pollack GM, et al. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 2000;20:381–6
   PubMed Web of Science ®Google Scholar
• Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab 2006;7:183–203
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RC, Smith BJ, et al. The impact of p-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos 2005;33:165–74
   PubMed Web of Science ®Google Scholar
• Maurer TS, DeBartolo DB, Tess DA, et al. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005;33:175–81
   PubMed Web of Science ®Google Scholar
• Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Del 2006;3:463–78
   PubMedGoogle Scholar
• Ieva E, Trapani A, Cioffi N, et al. Analytical characterization of chitosan nanoparticles for peptide drug delivery applications. Anal Bioanal Chem 2009;393:207–15
   PubMed Web of Science ®Google Scholar
• Md S, Khan RA, Mustafa G, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Biopharm 2013;48:393–405
   Web of Science ®Google Scholar
• Md S, Haque S, Fazil M, et al. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv 2014;11:827–42
   PubMed Web of Science ®Google Scholar
• Jafarieh O, Md S, Ali M, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi: 10.3109/03639045.2014.991400
   PubMed Web of Science ®Google Scholar
• Sharma S, Lohan S, Murthy RSR. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm 2014;40:869–78
   PubMed Web of Science ®Google Scholar
• Mittal D, Md S, Hasan Q, et al. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv 2014. [Epub ahead of print]. doi: 10.3109/10717544.2014.907372
   PubMedGoogle Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161:505–22
   PubMed Web of Science ®Google Scholar
• Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 2011;7:4169–76
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 2011;151:131–8
   PubMed Web of Science ®Google Scholar
• Gambaryan PY, Kondrasheva IG, Severin ES, et al. Increasing the efficiency of Parkinson's disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system. Exp Neurobiol 2014;23:246–52
   PubMedGoogle Scholar
• Zhao YZ, Li X, Lu CT, et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine 2014;10:755–64
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, et al. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv 2013;20:47–56
   PubMed Web of Science ®Google Scholar
• Pardeshi C, Rajput P, Belgamwar V, et al. Solid lipid based nanocarriers: an overview. Acta Pharm 2012;62:433–72
   PubMed Web of Science ®Google Scholar
• Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008;8:1696–702
   Web of Science ®Google Scholar
• Lawrence MJ, Rees GD. Microemulsion based media as a novel drug delivery system. Adv Drug Del Rev 2000;45:89–121
   PubMed Web of Science ®Google Scholar
• Kumar M, Pathak K. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm 2009;35:387–95
   PubMed Web of Science ®Google Scholar
• Mustafa G, Baboota S, Ahuja A, et al. Formulation development of chitosan coated intranasal ropinirole nanoemulsion for better management option of parkinson: an in vitro ex vivo evaluation. Curr Nanosci 2014;3:348–60
   Google Scholar